Bio Plus Co

Bio Plus Co CapEx/D&A

The CapEx to Depreciation Ratio of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 65.94. In the previous year, CapEx to Depreciation Ratio was 22.08 — a change of 198.65% (higher).

CapEx/D&A

65.94

YoY

198.65%

Last updated:

CapEx to Depreciation Ratio of Bio Plus Co is 2024 65.94 . CapEx to Depreciation Ratio of Bio Plus Co was 2023 22.08 . It decreases by 198.65% higher compared to the previous year.

The Bio Plus Co CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2019
14.31 KRW
Jan 1, 2020
6.41 KRW
Jan 1, 2021
44.12 KRW
Jan 1, 2022
8.72 KRW
Jan 1, 2023
22.08 KRW
Jan 1, 2024
65.94 KRW
The Bio Plus Co CapEx/D&A history
YEARCapEx/D&AYoY
65.94+198.65%
22.08+153.16%
8.72-80.23%
44.12+588.11%
6.41-55.21%
14.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

CapEx to Depreciation Ratio of Bio Plus Co is 65.94 in 2024.

CapEx to Depreciation Ratio of Bio Plus Co changed from 22.08 to 65.94, representing a 198.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Plus Co

All Key Metrics — Bio Plus Co